Armistice Capital, LLC Rigel Pharmaceuticals Inc Transaction History

Armistice Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.12 - $1.57 $1.95 Million - $2.73 Million	-1,740,000 Reduced 10.18%	15,360,000 $22.7 Million
Q4 2023 Feb 13, 2024	SELL	$0.72 - $1.56 $25,920 - $56,160	-36,000 Reduced 0.21%	17,100,000 $24.8 Million
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.39 $38,520 - $50,040	36,000 Added 0.21%	17,136,000 $18.5 Million
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $85,120 - $138,320	76,000 Added 0.45%	17,100,000 $22.1 Million
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $85,000 - $136,000	68,000 Added 0.4%	17,024,000 $22.5 Million
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $9.05 Million - $161 Million	13,503,126 Added 391.07%	16,956,000 $25.4 Million
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $3.8 Million - $42.1 Million	3,452,874 New	3,452,874 $4.07 Million
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $930,406 - $2.16 Million	-522,700 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $737,007 - $1.07 Million	522,700 New	522,700 $957,000

355K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.